Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
ALK2-IN-2
Cat. No.:
OB0225LY-0206
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
ALK2-IN-2 is a selective ALK2 inhibitor mainly used to regulate bone formation-related signaling pathways.
Synonym:
2254409-25-9; 4-[6-[4-(1-Pyrrolidin-1-ylethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]naphthalene-1-sulfonamide; 4-(6-(4-(1-(Pyrrolidin-1-yl)ethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)naphthalene-1-sulfonamide
CAS No.:
2254409-25-9
Compound CID:
138454752
Formula:
C28H27N5O2S
Formula Weight:
497.61
Specification
Relative Density:
1.38 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ALK2-IN-2 can be used to study the mechanisms of bone metabolism, osteoblast function and related diseases.
Library Information
Targets:
TGF-beta/Smad; ALK family
Receptors:
ALK2; ALK3; TGF-β receptor
Pathways:
Stem cells; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-3
Plate Location:
e10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
112.5 mg/mL; 226.1 mM
